vs
Fulgent Genetics, Inc.（FLGT）与REGIS CORP（RGS）财务数据对比。点击上方公司名可切换其他公司
Fulgent Genetics, Inc.的季度营收约是REGIS CORP的1.5倍（$83.3M vs $57.1M），REGIS CORP净利率更高（0.8% vs -28.1%，领先28.9%），REGIS CORP同比增速更快（22.3% vs 9.3%），REGIS CORP自由现金流更多（$891.0K vs $-83.1M），过去两年Fulgent Genetics, Inc.的营收复合增速更高（13.7% vs 7.8%）
Fulgent Genetics是一家分子诊断技术企业，开发并提供覆盖携带者筛查、肿瘤基因检测、传染病检测、遗传性疾病分析的多元基因检测服务，主要客户为北美地区的医疗机构、药企、科研院所及公共卫生组织。
瑞吉斯公司是一家美国美发沙龙运营商，总部位于明尼苏达州明尼阿波利斯市。截至2021年8月，该集团旗下拥有5563家加盟沙龙以及276家直营门店，是北美地区规模领先的美发沙龙连锁经营企业。
FLGT vs RGS — 直观对比
营收规模更大
FLGT
是对方的1.5倍
$57.1M
营收增速更快
RGS
高出12.9%
9.3%
净利率更高
RGS
高出28.9%
-28.1%
自由现金流更多
RGS
多$84.0M
$-83.1M
两年增速更快
FLGT
近两年复合增速
7.8%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $83.3M | $57.1M |
| 净利润 | $-23.4M | $456.0K |
| 毛利率 | 39.1% | — |
| 营业利润率 | -43.5% | 10.8% |
| 净利率 | -28.1% | 0.8% |
| 营收同比 | 9.3% | 22.3% |
| 净利润同比 | -297.7% | -94.0% |
| 每股收益（稀释后） | — | $0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FLGTRGS
| Q4 25 | $83.3M | $57.1M | ||
| Q3 25 | $84.1M | $59.0M | ||
| Q2 25 | $81.8M | $60.4M | ||
| Q1 25 | $73.5M | $57.0M | ||
| Q4 24 | $76.2M | $46.7M | ||
| Q3 24 | $71.7M | $46.1M | ||
| Q2 24 | $71.0M | $49.4M | ||
| Q1 24 | $64.5M | $49.2M |
净利润FLGTRGS
| Q4 25 | $-23.4M | $456.0K | ||
| Q3 25 | $-6.6M | $1.4M | ||
| Q2 25 | $-19.0M | $116.5M | ||
| Q1 25 | $-11.5M | $250.0K | ||
| Q4 24 | $-5.9M | $7.6M | ||
| Q3 24 | $-14.6M | $-853.0K | ||
| Q2 24 | $-8.7M | $91.2M | ||
| Q1 24 | $-13.5M | $-2.3M |
毛利率FLGTRGS
| Q4 25 | 39.1% | — | ||
| Q3 25 | 42.2% | — | ||
| Q2 25 | 42.1% | — | ||
| Q1 25 | 38.6% | — | ||
| Q4 24 | 41.8% | — | ||
| Q3 24 | 37.3% | — | ||
| Q2 24 | 37.3% | — | ||
| Q1 24 | 34.3% | — |
营业利润率FLGTRGS
| Q4 25 | -43.5% | 10.8% | ||
| Q3 25 | -18.3% | 10.0% | ||
| Q2 25 | -24.1% | 12.1% | ||
| Q1 25 | -26.9% | 8.8% | ||
| Q4 24 | -21.2% | 11.8% | ||
| Q3 24 | -23.8% | 4.6% | ||
| Q2 24 | -26.6% | — | ||
| Q1 24 | -33.8% | 8.3% |
净利率FLGTRGS
| Q4 25 | -28.1% | 0.8% | ||
| Q3 25 | -7.9% | 2.3% | ||
| Q2 25 | -23.2% | 192.9% | ||
| Q1 25 | -15.7% | 0.4% | ||
| Q4 24 | -7.7% | 16.4% | ||
| Q3 24 | -20.4% | -1.9% | ||
| Q2 24 | -12.3% | 184.7% | ||
| Q1 24 | -20.9% | -4.7% |
每股收益（稀释后）FLGTRGS
| Q4 25 | — | $0.16 | ||
| Q3 25 | — | $0.49 | ||
| Q2 25 | — | $43.67 | ||
| Q1 25 | — | $0.08 | ||
| Q4 24 | — | $2.71 | ||
| Q3 24 | — | $-0.36 | ||
| Q2 24 | — | $38.40 | ||
| Q1 24 | — | $-1.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $50.2M | $18.4M |
| 总债务越低越好 | — | $113.3M |
| 股东权益账面价值 | $1.1B | $188.7M |
| 总资产 | $1.2B | $588.3M |
| 负债/权益比越低杠杆越低 | — | 0.60× |
8季度趋势，按日历期对齐
现金及短期投资FLGTRGS
| Q4 25 | $50.2M | $18.4M | ||
| Q3 25 | $117.6M | $16.6M | ||
| Q2 25 | $87.9M | $17.0M | ||
| Q1 25 | $67.3M | $13.3M | ||
| Q4 24 | $55.1M | $10.2M | ||
| Q3 24 | $58.0M | $6.3M | ||
| Q2 24 | $65.1M | $10.1M | ||
| Q1 24 | $54.7M | $5.9M |
总债务FLGTRGS
| Q4 25 | — | $113.3M | ||
| Q3 25 | — | $111.3M | ||
| Q2 25 | — | $110.8M | ||
| Q1 25 | — | $112.0M | ||
| Q4 24 | — | $111.5M | ||
| Q3 24 | — | $95.2M | ||
| Q2 24 | — | $99.5M | ||
| Q1 24 | — | $179.7M |
股东权益FLGTRGS
| Q4 25 | $1.1B | $188.7M | ||
| Q3 25 | $1.1B | $187.6M | ||
| Q2 25 | $1.1B | $185.6M | ||
| Q1 25 | $1.1B | $68.6M | ||
| Q4 24 | $1.1B | $66.7M | ||
| Q3 24 | $1.1B | $56.4M | ||
| Q2 24 | $1.1B | $56.8M | ||
| Q1 24 | $1.1B | $-35.8M |
总资产FLGTRGS
| Q4 25 | $1.2B | $588.3M | ||
| Q3 25 | $1.2B | $592.1M | ||
| Q2 25 | $1.2B | $599.0M | ||
| Q1 25 | $1.2B | $511.2M | ||
| Q4 24 | $1.2B | $530.1M | ||
| Q3 24 | $1.2B | $508.9M | ||
| Q2 24 | $1.2B | $530.5M | ||
| Q1 24 | $1.2B | $543.7M |
负债/权益比FLGTRGS
| Q4 25 | — | 0.60× | ||
| Q3 25 | — | 0.59× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | — | 1.63× | ||
| Q4 24 | — | 1.67× | ||
| Q3 24 | — | 1.69× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-78.1M | $1.7M |
| 自由现金流经营现金流 - 资本支出 | $-83.1M | $891.0K |
| 自由现金流率自由现金流/营收 | -99.7% | 1.6% |
| 资本支出强度资本支出/营收 | 6.0% | 1.4% |
| 现金转化率经营现金流/净利润 | — | 3.65× |
| 过去12个月自由现金流最近4个季度 | $-124.2M | $14.9M |
8季度趋势，按日历期对齐
经营现金流FLGTRGS
| Q4 25 | $-78.1M | $1.7M | ||
| Q3 25 | $11.1M | $2.3M | ||
| Q2 25 | $-30.2M | $6.8M | ||
| Q1 25 | $-4.4M | $6.2M | ||
| Q4 24 | $25.0M | $2.1M | ||
| Q3 24 | $-15.5M | $-1.3M | ||
| Q2 24 | $4.3M | $5.1M | ||
| Q1 24 | $7.3M | $-277.0K |
自由现金流FLGTRGS
| Q4 25 | $-83.1M | $891.0K | ||
| Q3 25 | $5.1M | $1.9M | ||
| Q2 25 | $-37.0M | $6.2M | ||
| Q1 25 | $-9.1M | $5.9M | ||
| Q4 24 | $21.2M | $1.7M | ||
| Q3 24 | $-35.0M | $-1.4M | ||
| Q2 24 | $-8.7M | $5.1M | ||
| Q1 24 | $3.2M | $-326.0K |
自由现金流率FLGTRGS
| Q4 25 | -99.7% | 1.6% | ||
| Q3 25 | 6.0% | 3.2% | ||
| Q2 25 | -45.2% | 10.3% | ||
| Q1 25 | -12.5% | 10.3% | ||
| Q4 24 | 27.9% | 3.6% | ||
| Q3 24 | -48.8% | -3.0% | ||
| Q2 24 | -12.2% | 10.3% | ||
| Q1 24 | 5.0% | -0.7% |
资本支出强度FLGTRGS
| Q4 25 | 6.0% | 1.4% | ||
| Q3 25 | 7.2% | 0.7% | ||
| Q2 25 | 8.3% | 0.9% | ||
| Q1 25 | 6.4% | 0.6% | ||
| Q4 24 | 5.0% | 0.9% | ||
| Q3 24 | 27.2% | 0.0% | ||
| Q2 24 | 18.2% | 0.0% | ||
| Q1 24 | 6.3% | 0.1% |
现金转化率FLGTRGS
| Q4 25 | — | 3.65× | ||
| Q3 25 | — | 1.68× | ||
| Q2 25 | — | 0.06× | ||
| Q1 25 | — | 24.80× | ||
| Q4 24 | — | 0.28× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.06× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FLGT
| Precision Diagnostics | $48.3M | 58% |
| Anatomic Pathology | $27.0M | 32% |
| Biopharma Services | $7.8M | 9% |
RGS
| Franchise Segment | $37.9M | 66% |
| Royalty | $13.6M | 24% |
| Other | $2.8M | 5% |
| Fees | $1.8M | 3% |
| Franchise Fees | $1.0M | 2% |
